Compare NetApp Inc. (NTAP) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Sana Biotechnology Inc — how do they compare? NetApp Inc. trades at $184.74 (market cap $36.29B), while Sana Biotechnology Inc trades at $3.17 (market cap $947.48M). The key difference: NetApp Inc. is far larger — about 38.3× Sana Biotechnology Inc's market cap, and NetApp Inc. pays a 1.13% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NTAP | SANA | |
|---|---|---|
Market Cap | $36.29B | $947.48M |
Sector | Technology | Health |
52-Week High | $207.08 | $5.92 |
52-Week Low | $94.11 | $2.68 |
Enterprise Value | $35.24B | $860.73M |
Dividend Yield | 1.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $189.13, up 1.91% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows robust fundamentals, including a 70.63% gross margin and 19.19% net income margin, supported by record quarterly results and raised fiscal 2027 guidance. Analyst consensus is a buy with a $193.55 price target, though valuation metrics like a P/E of 26.71 indicate a premium. Recent news highlights AI-driven demand and cloud growth as key catalysts.
Outlook remains positive due to AI storage momentum and operational strength, but risks include premium valuation pressure and margin challenges. The stock offers growth potential from hybrid cloud expansion, yet investors should monitor execution against high expectations and competitive dynamics in the data infrastructure sector.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
